Rituximab therapy has been associated with more severe COVID-19 infection in persons with multiple sclerosis,1,2 although this finding was based on a small number of events. Further research is needed to evaluate the potential increased risk for severe disease. In this study, we examined the association between timing and dose of rituximab and hospitalization for COVID-19 across Sweden.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: October 5, 2021.
Published: December 1, 2021. doi:10.1001/jamanetworkopen.2021.36697
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 McKay KA et al. JAMA Network Open.
Corresponding Author: Thomas Frisell, PhD, Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet, T2, Karolinska University Hospital, 171 76 Stockholm, Sweden (email@example.com).
Author Contributions: Dr McKay had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: McKay, Piehl, Langer-Gould, Frisell.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: McKay, Piehl.
Critical revision of the manuscript for important intellectual content: Piehl, Englund, He, Langer-Gould, Hillert, Frisell.
Statistical analysis: McKay, Langer-Gould, Frisell.
Obtained funding: Piehl, Langer-Gould, Hillert.
Administrative, technical, or material support: Piehl, He, Frisell.
Supervision: Piehl, Hillert.
Conflict of Interest Disclosures: Dr McKay reported receiving research funding from the Swedish Research Council for Health, Working Life and Welfare. Dr Piehl reported receiving grants from Swedish Medical Research Council, County of Stockholm, Merck KGaA, UCB, and Sanofi-Genzyme as well as personal fees from Parexel and Roche outside the submitted work. Dr Hillert reported receiving grants from Biogen, Celgene, Merck KGaA, Novartis, Bristol Myers Squibb, Roche, and Sanofi-Genzyme; personal fees from Biogen, Celgene, Sanofi-Genzyme, Merck KGaA, Novartis, Teva, Janssen, and Sandoz; and research funding from Swedish Research Council and the Swedish Brain Foundation outside the submitted work. Dr Frisell reported receiving research funding from the Swedish Research Council and NEURO Sweden. No other disclosures were reported.
Funding/Support: This study was supported by the Patient-Centered Outcomes Research Institute (PCORI/MS-1511-33196).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.